Oxford Cannabinoid Technologies (OCT) is a UK-based pharmaceutical company specialised in cannabinoid drug development. The Company’s vision is to become a global leader in developing licensed prescription medicines that target the endocannabinoid system and address significant unmet medical needs.
The Group’s primary market focus is the total addressable pain market, which is estimated to be worth at least £42.5 billion by commercialisation of the first drug produced by OCT, currently anticipated to be in 2027, and as such it initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.
Having produced the prospectus relating to their Main Market IPO on the London Stock Exchange in May this year, the Perivan shareholder communications team were delighted to be invited to design and produce OCT’s first ever annual report as a quoted company which was successfully published and posted to their new shareholders.
To view the full annual report, click here.
Perivan specialise in the production and publication of financial documents relating to shareholder and investor communications for quoted companies, private companies and open and closed-ended funds.